Cigna Investments Inc Exelixis, Inc. Transaction History

Cigna Investments Inc

  • $568 Million
  • Q3 2024

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$15.84 - $21.88 $152,982 - $211,317
-9,658 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$16.3 - $21.14 $157,425 - $204,170
9,658 New
9,658 $204,000
Q2 2021

Aug 10, 2021
SELL
$17.95 - $25.56 $200,286 - $285,198
-11,158 Closed
0 $0
Q1 2021

May 10, 2021
BUY
$20.53 - $25.22 $11,394 - $13,997
555 Added 5.23%
11,158 $252,000
Q4 2020

Feb 11, 2021
BUY
$18.39 - $24.8 $17,599 - $23,733
957 Added 9.92%
10,603 $212,000
Q3 2020

Nov 12, 2020
SELL
$20.67 - $26.94 $127,926 - $166,731
-6,189 Reduced 39.08%
9,646 $237,000
Q2 2020

Aug 17, 2020
BUY
$16.46 - $27.42 $260,644 - $434,195
15,835 New
15,835 $375,000
Q2 2019

Aug 12, 2019
SELL
$18.93 - $24.75 $224,225 - $293,163
-11,845 Closed
0 $0
Q1 2019

May 10, 2019
BUY
$19.6 - $24.76 $232,162 - $293,282
11,845 New
11,845 $282,000
Q3 2018

Nov 13, 2018
SELL
$15.87 - $22.4 $223,243 - $315,100
-14,067 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$18.56 - $22.45 $261,083 - $315,804
14,067 New
14,067 $302,000
Q1 2018

May 09, 2018
SELL
$22.15 - $31.89 $211,953 - $305,155
-9,569 Closed
0 $0
Q4 2017

Jan 26, 2018
SELL
$24.23 - $30.93 $1,744 - $2,226
-72 Reduced 0.75%
9,569 $291,000
Q3 2017

Oct 11, 2017
BUY
$23.35 - $29.24 $225,117 - $281,902
9,641
9,641 $233,000

Others Institutions Holding EXEL

# of Institutions
503
Shares Held
244M
Call Options Held
2.54M
Put Options Held
2.29M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Cigna Investments Inc Portfolio

Follow Cigna Investments Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cigna Investments Inc , based on Form 13F filings with the SEC.

News

Stay updated on Cigna Investments Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email